Organogenesis Holdings Inc. ORGOW 深 滬
交易中 01-28 11:13:43 美东时间
0.21
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.21
- 總市值 0
- 52周最高 0.21
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.21
- 委 比 0.00%
- 總股本 --
- 歷史最高 0.21
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.21
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BTIG Reiterates Buy on Organogenesis Holdings, Maintains $9 Price Target
BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Buy and maintains $9 price target.
2025-12-26 19:02
Organogenesis Initiates Rolling Submission Of BLA To FDA For ReNu; Plans To Complete BLA Submission With Final Modules Submitted In H1 Of 2026
Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports
2025-12-24 05:07
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Organogenesis Holdings Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis treatment. The final BLA modules are expected by mid-2026. ReNu, which has been studied in over 1,300 patients, could be the first non-surgical biologic therapy for knee osteoarthritis pain, particularly for severe cases. Knee OA affects millions of Ameri...
2025-12-23 21:05
Market-Moving News for December 16th
RILY: 50% | B. Riley Financial shares are trading higher after the company reported better-than-expected Q2 financial results. ORGO: 24% | Organogenesis Holdings shares are trading higher after the company
2025-12-16 20:29
Biggest stock movers Tuesday: RILY, ORGO, KYTX, RC, LWLG and more
U.S. stock futures retreated Tuesday as investors adopted a cautious stance ahead of November’s employment data, a key indicator for the labor market’s health. Here are some of Tuesday's biggest stock...
2025-12-16 18:17
Organogenesis Holdings Completes Type-B Meeting With FDA Resulting In Confirmation To Initiate Rolling BLA For ReNu Planned Before December End
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative
2025-12-16 05:28
BTIG Maintains Buy on Organogenesis Holdings, Raises Price Target to $9
BTIG analyst Ryan Zimmerman maintains Organogenesis Holdings (NASDAQ:ORGO) with a Buy and raises the price target from $7 to $9.
2025-11-20 20:51
Organogenesis Holdings Reports Record Revenue, Raises Guidance
Organogenesis Holdings ( ($ORGO) ) has released its Q3 earnings. Here is a brea...
2025-11-07 13:54
Organogenesis Holdings Raises FY2025 Net product revenue Guidance from $480.000M-$510.000M to $500.000M-$525.000M.
Organogenesis Holdings (NASDAQ:ORGO) raises FY2025 Net product revenue outlook from $480.000 million-$510.000 million to $500.000 million-$525.000 million.
2025-11-07 07:12
Organogenesis Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.
Organogenesis Holdings shares are trading higher after the company reported bet...
2025-11-07 06:00
